BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bai Y, Kim JY, Bisunke B, Jayne LA, Silvaroli JA, Balzer MS, Gandhi M, Huang KM, Sander V, Prosek J, Cianciolo RE, Baker SD, Sparreboom A, Jhaveri KD, Susztak K, Bajwa A, Pabla NS. Kidney toxicity of the BRAF-kinase inhibitor vemurafenib is driven by off-target ferrochelatase inhibition. Kidney Int 2021:S0085-2538(21)00855-3. [PMID: 34534550 DOI: 10.1016/j.kint.2021.08.022] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Lu D, Hao W, Hong P, Zhang X, Zhao X, Ma L, Ping H. Critical role of VHL/BICD2/STAT1 axis in crystal-associated kidney disease.. [DOI: 10.21203/rs.3.rs-2050640/v1] [Reference Citation Analysis]
2 Dailey HA, Medlock AE. A primer on heme biosynthesis. Biol Chem 2022. [PMID: 36029525 DOI: 10.1515/hsz-2022-0205] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Frazier KS. Kidney Effects by Alternative Classes of Medicines in Patients and Relationship to Effects in Nonclinical Toxicity Studies. Toxicol Pathol 2022;:1926233221100414. [PMID: 35608030 DOI: 10.1177/01926233221100414] [Reference Citation Analysis]
4 Obi CD, Bhuiyan T, Dailey HA, Medlock AE. Ferrochelatase: Mapping the Intersection of Iron and Porphyrin Metabolism in the Mitochondria. Front Cell Dev Biol 2022;10:894591. [DOI: 10.3389/fcell.2022.894591] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
5 Yamada R, Yanagita M. Unexpected cause of vemurafenib-induced nephrotoxicity: ferrochelatase. Kidney Int 2021;100:1158-60. [PMID: 34802553 DOI: 10.1016/j.kint.2021.09.010] [Reference Citation Analysis]